Topics

STAT Plus: Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews

15:22 EDT 12 Sep 2019 | STAT

Despite the hubbub over the “right-to-try” law, a recent survey found that nearly half of drug makers would want regulators to review a decision to provide an experimental treatment.

Original Article: STAT Plus: Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...